大会集中展示了一批颠覆性科技成果，如上海交通大学的"脑机接口专用芯片""魔方无人机系统"、华山医院的"脑胶质瘤治疗性DC疫苗"、华东师范大 学的"新型高端酶制剂"等，多项技术处于国际领先水平。 6家面向未来产业的概念验证平台首次集体亮相，涵盖脑机接口、核酸药物、基因编辑、集成电路材料等领域，通过全链条服务有效降低早期成果转化 风险。 科技成果转化共享汇展区同样成果丰硕，清华大学展示的原子量子计算机、仁济医院的"框架核酸分子计算诊断芯片与器件"等，彰显了高校与医疗机构 在源头创新方面的强大能力。 9月20日至22日，以"万'象'需求·全球揭榜"为主题的2025 InnoMatch技术转移大会在上海浦东张江科学会堂举行。 作为国内首个以"创新需求"为导向的科技盛会，本届大会聚焦"创新需求、人才支撑、资本力量"，搭建了一个集需求、成果、人才、资本等多要素于一 体的国际化对接平台，成效显著，三天完成10000+线上线下对接，共达成近90亿的意向合作金额，展现了上海在技术转移领域的创新实践与蓬勃活力，为 加快推进上海国际科创中心建设提供了坚实支撑。 首发首秀、概念验证等多板块协同发力 大会期间，共发布技术需求超1000 ...

Core Insights - The 2025 InnoMatch Technology Transfer Conference opened in Shanghai, focusing on demand-driven innovation, talent discovery, and capital empowerment [1] - The conference introduced a "1+3+365" model for continuous engagement, showcasing over 10,000 technology demands and attracting investments exceeding 20 billion yuan [1][2] - The event highlighted significant innovations in various fields, including artificial intelligence, quantum technology, and biomedicine, with over 2,000 job postings and 1,728 technology transfer results presented [1][2] Group 1: Demand and Innovation - The conference featured over 120 industry-leading companies showcasing open innovation platforms and demand scenarios, including a major project for electric vehicle charging stations in Kazakhstan [2] - Notable innovations included brain-computer interface chips and advanced medical technologies from Shanghai Jiao Tong University and Huashan Hospital, demonstrating international leadership in their respective fields [2][4] - The event emphasized the integration of innovation chains, industry chains, capital chains, and talent chains in the Yangtze River Delta region [2] Group 2: Concept Validation and Standards - Six high-quality concept validation platforms were launched, providing comprehensive services to reduce risks and costs associated with future industry innovations [3] - The conference announced the release of the "2025 Annual Report on the Transformation of Scientific and Technological Achievements" and the "2025 Shanghai White Paper on the Transformation of Scientific and Technological Achievements" [5] - New standards for evaluating scientific achievements in medical institutions and guidelines for concept validation institutions were introduced to promote a sustainable ecosystem for technology transfer [5] Group 3: Market Engagement and Collaboration - The conference featured a "Technology Trading Market" where innovative products were promoted, attracting significant audience engagement [6] - The "Transformation Clinic" provided one-on-one consultations for over 374 projects, with 19 projects entering the pre-concept validation stage and contracts exceeding 300 million yuan [6] - The event is part of Shanghai's strategy to enhance its global influence in technology innovation and create a modern industrial system [6][7]

Group 1: Surgical Robotics - Recent advancements in surgical robotics include a remote single-port laparoscopic surgical robot used for rectal tumor removal, demonstrating the potential for remote surgeries over long distances [1][3] - The surgery was performed by a team in Shanghai while the patient was located in Jiangxi, showcasing the capabilities of the robot in challenging surgical environments [1][3] - The robot was modified based on feedback from surgeons, improving its functionality for complex procedures [5][7] - The collaboration between hospitals and tech companies has led to breakthroughs in domestic surgical robot development, overcoming patent barriers of traditional multi-port robots [9] Group 2: Non-invasive Blood Glucose Monitoring - A new non-invasive blood glucose meter has been developed, allowing patients to measure their blood sugar without finger pricks, addressing compliance issues associated with traditional methods [10][12] - The device uses near-infrared laser technology to measure glucose levels, achieving over 99% accuracy compared to traditional venous blood tests [18] - The innovation aims to enhance patient experience and could lead to the development of wearable devices for continuous glucose monitoring [16][20] Group 3: Stem Cell Drug Development - China has become a leader in new drug development, with over 20% of global new drugs in research, including the first domestically approved stem cell drug for acute graft-versus-host disease [21][26] - The stem cell drug offers a significant cost advantage, priced around 20,000 RMB compared to 190,000 USD for similar products in the US, reducing the financial burden on patients [25] - The approval of this drug marks a shift towards multi-target treatment approaches in complex diseases, enhancing treatment options for patients [25][26]

Group 1 - A series of innovative medical technologies were showcased at the "Intelligent Medical Engineering Innovation Development Forum" held on June 26, including surgical robots, non-invasive blood glucose meters, AI thermal therapy devices, and surgical navigation robots [1] - Surgical robots are being utilized in various procedures such as cerebrovascular intervention, prostate puncture, and autonomous oral implant surgery, addressing clinical challenges like radiation exposure for doctors during traditional procedures [1] - The non-invasive blood glucose meter demonstrated a pain-free and more accurate method of blood glucose testing, achieving a 94.5% consistency with venous blood results [1] Group 2 - Since the first Intelligent Medical Engineering Conference in May of last year, the Fengtai District has established a health industry task force with over 200 top experts and created an innovation service center for the health industry [2] - The district has attracted several enterprises and institutions, including the Tian Tan International Brain Health Center and Siemens Medical's first open medical engineering transformation platform, facilitating the clinical application of innovative products [2]

Core Viewpoint - The article presents a series of investment roadshows featuring innovative medical technology companies seeking funding, highlighting their unique products and market potential. Group 1: Company Presentations - **Qiwai Medical Technology (Shenzhen) Co., Ltd.** is focused on developing and selling innovative heart failure intervention devices, including drug balloons and microcatheters, with a unique non-implantable technology for heart failure treatment [1]. - **Wuxi Nianhuan Technology Co., Ltd.** specializes in health and service robots, aiming to assist the elderly, children, and disabled individuals with multifunctional smart walking robots, leveraging strong academic partnerships for technological development [2]. - **Anhui Shuo Jin Medical Equipment Co., Ltd.** provides MRI-compatible system solutions, focusing on the transition from diagnosis to treatment in MRI applications [3]. - **Jiangsu Jingce Medical Technology Co., Ltd.** is developing a non-invasive blood glucose meter, indicating advancements in diabetes management technology [4]. - **Nasjia Biotechnology (Jiaxing) Co., Ltd.** is working on biological materials for treating pathological high myopia, currently in clinical trial stages, showcasing innovative surgical techniques [5]. - **Zhejiang Yingjia Medical Equipment Co., Ltd.** is engaged in the research and production of bronchoscopic navigation devices, with clinical trials already underway, demonstrating early-stage product validation [6].

Core Insights - The 2025 JD Service Provider Ecosystem Partner Conference was held in Beijing, attracting over 500 service providers to recognize outstanding partners in transaction scale, service quality, fulfillment efficiency, and merchant satisfaction [1] - JD officially launched the "Service Provider Empowerment Plan," focusing on three core dimensions: business opportunity empowerment, rights empowerment, and experience empowerment, to provide comprehensive support for service providers [1][5] - The JD retail platform's ecosystem department emphasized the importance of service providers in the deep construction of the JD merchant ecosystem, with plans to increase support for partners in 2025 [1] Group 1 - The "JD Excellence" award recognized 120 outstanding service providers and 10 trainers across various categories such as operation, content marketing, customer service outsourcing, and software tools [1] - The JD Mai Service Market integrates third-party cooperation forces, including service providers, ISVs, and trainers, to offer solutions for merchants' digital transformation and refined operations [3] - In 2024, the number of merchants using JD Mai Service Market software tools and operational services grew nearly 40% year-on-year, with a 220% increase in merchants using operation services and a nearly 300% increase in those using advertising services [3] Group 2 - The case of E-DAWN flagship store illustrates the effectiveness of the strategies implemented by award-winning service providers, achieving sales of 98,000 yuan in the first month and 1 million yuan in the first 60 days [4] - The "Service Provider Empowerment Plan" aims to create a comprehensive and multi-dimensional empowerment system for service providers, helping them reduce costs and increase efficiency [5] - The ongoing implementation of the "Service Provider Empowerment Plan" is expected to bring vitality to the JD merchant ecosystem, fostering open and efficient cooperation between service providers and merchants [5]

Group 1: Ganyuan Food - Ganyuan Food plans to conduct in-depth research in the Southeast Asian market starting in Q4 2024, with an accelerated product export strategy in 2025 [1] - The company is addressing raw material fluctuations through advance reserves, supply chain alternatives, and increasing direct procurement [1] - The growth in accounts receivable is primarily due to the staggered impact of the Spring Festival, leading to increased receivables during peak sales periods [1] - The growth of mixed nuts and bean snacks is attributed to bulk snack channels and overseas markets [1] - A significant promotional effort in Q1 2024 resulted in lower e-commerce gross margins, but gross margins are expected to rise year-on-year in Q1 2025 [1] - Sales expenses in Q1 2025 are expected to increase due to the initiation of the Southeast Asia export strategy, including market research, product design, sales personnel costs, and new celebrity endorsement fees [1] Group 2: Lepu Medical - Lepu Medical is optimistic about future profit growth from structural heart, dermatology, and neuro-regulation businesses [2] - The company has set profit margin assessments for each business segment and is controlling costs to maintain healthy cash flow [2] - The trend of centralized procurement may moderate, with significant regional differences across provinces [2] - The impact of US-China tariffs on the company is limited, and the domestic substitution process for some products may accelerate [2] - The promotion of new cardiovascular interventional products is progressing smoothly, with a sales target for coronary interventional business set for a 10% year-on-year increase [2] - The non-invasive blood glucose meter is undergoing further testing, and the candidate drug MWN101 has completed Phase II clinical trials [2] - The brain-computer interface business is in the incubation stage, and the market share of coronary stents has not met expectations, prompting increased focus on this area [2] - The AI business will increasingly integrate with hardware devices, and opportunities exist for DSA product promotion amid US-China trade tensions [2] - The company is placing greater emphasis on the neuro-regulation pipeline due to competition in the cardiac electrophysiology sector [2] - The TAVR product aims to enhance its popularity through reasonable pricing [2] Group 3: Baike Biotech - Baike Biotech experienced significant declines in performance for 2024 and Q1 2025, with decreases of 32.64% and 39.96% respectively, primarily due to the impact on shingles vaccine sales [3] - The company plans to enhance market awareness of the shingles vaccine through various methods while maintaining its position in the chickenpox vaccine market and expanding into international markets [3] - In terms of R&D, multiple projects have made progress, including liquid nasal spray flu vaccines and rabies monoclonal antibodies [3] - The company anticipates an increase in R&D investment and sales expense ratios in 2025, followed by a gradual decline [3]

Group 1 - The core viewpoint of the article highlights that Ningju Asset has conducted research on Lepu Medical, focusing on its future profit growth expectations from various business segments including structural heart, dermatology, and neuroregulation [1] - Lepu Medical has set profit margin assessments for each business segment and aims to control costs to maintain healthy cash flow [1] - The trend of centralized procurement may become milder, with significant differences across provinces [1] - The impact of US-China tariffs on the company is limited, and the domestic substitution process for some products may accelerate [1] - The sales target for coronary intervention business is a 10% year-on-year growth, with successful promotion of new products [1] - The non-invasive blood glucose meter is undergoing further testing [1] - The candidate drug MWN101 has completed phase II clinical trials [1] - The brain-computer interface business is in the incubation stage [1] - The market share of coronary stents has not met expectations, leading the company to place more emphasis on this business since last year [1] - The AI business will increasingly integrate with hardware devices [1] - Opportunities exist for DSA product promotion due to the backdrop of US-China economic and trade disputes [1] - The cardiac electrophysiology sector is crowded, prompting the company to focus more on the neuroregulation pipeline [1] - The TAVR product aims to enhance its popularity through reasonable pricing [1] Group 2 - Ningju Investment is a professional institution focused on investment research in the financial securities market, providing various asset management services to institutional investors and high-net-worth clients [2] - It is one of the first 100 private fund management companies approved for registration in China [2] - Ningju Investment manages over 30 private funds across six major series, with investment scope covering bonds, stocks, futures, options, and various structured financial products [2]

聚焦产业强基、科创策源，嘉定新城将加快培育新质生产力： ——锚定产业细分赛道，编制嘉定新城"医疗器械和高端医疗装备"细分赛道专项产业规划，在联影小 镇、械谷、杏谷等产业园区推动相关重大项目落地。去年新城范围内医疗器械产值增长达10.4%，今年 生物医药产业力争增长15%。 ——提升科创策源功能，加强产教融合、院地合作，推动龙头科技企业开展关键核心技术研发；联合瑞 金医院积极发展"产学研医"一体化模式，在上海械谷创新医疗器械产业园区成立嘉定瑞金创新中心，成 功研发了"无创血糖仪"等先进医疗器械。 ——推动实施重大项目，积极推动智能网联汽车技术商业化，支持氢燃料电池汽车示范应用，加快推动 上汽清陶固态电池研发量产；加快汽车芯谷首发项目建设进度，做强上海汽车芯片工程中心等重要平台 能级；推进核能装备、低空经济、新型储能、人工智能、工业互联网等重点产业项目。 上海嘉定区相关人士表示，聚焦功能优化、品质提升，将不断增强嘉定新城的辐射能级，在加大交通先 导连通的基础上，凸显文化的辐射影响，打造文化新空间和城市会客厅重要展示窗口；在嘉定老城，推 进州桥景区更新改造，推动西门历史文化街区先行启动区年内开放；新城与老城依托横沥 ...

Core Viewpoint - Lepu Medical's overall revenue declined by 23.52% in 2024, with significant impacts across multiple business segments, leading to a drastic drop in net profit by 80.37% [2][3] Group 1: 2024 Performance Overview - The medical device segment's revenue decreased by 9.47%, primarily due to a significant drop in the in vitro diagnostics business, although coronary intervention and structural heart disease businesses grew by 6.35% and 44.03% respectively [2] - The pharmaceutical segment experienced a notable decline, with raw material drug revenue down by 14.99% and formulation revenue down by 46.50%, largely due to the impact of the "Four Same" policy and price reductions from centralized procurement [2] - The medical services and health management segment saw a revenue decline of 19.24%, attributed to reduced demand for blood oxygen products [2] - The company reduced its workforce by 1,409 employees to optimize operations, focusing on R&D and marketing personnel in specific segments [2] Group 2: 2025 Outlook - Lepu Medical holds a cautiously optimistic view for 2025, anticipating a 30% year-on-year increase in pharmaceutical shipments, with formulation revenue expected to reach around 1.8 billion [3] - The medical device segment is projected to grow by approximately 10%, driven by cardiovascular intervention products, with expected growth rates of 10-15% for specific product lines [3] - The medical services and health management segment is expected to grow by 15%, supported by new business from specific hospitals and foreign trade [3] - The company is preparing for the approval of new dermatological injection products, which are anticipated to enhance revenue streams [3] Group 3: Investor Q&A Highlights - The company is focusing on controlling sales expenses and reducing ineffective R&D to improve profit margins [4] - Future profit growth is expected to come from structural heart, dermatology, and neuro-modulation businesses, although profit forecasts for 2026 remain uncertain [4] - The company is addressing the impact of centralized procurement policies, with expectations of moderate trends and varying implementations across provinces [4] - Key product sales targets include 20 million for TAVR, 50 million for peripheral intervention, and a total of 250 million for coronary and peripheral intervention products [4]